The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Managing drug resistance in CP-CML with ponatinib and asciminib
Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, addresses the management of resistant chronic myeloid leukemia in the chronic phase (CP-CML). Findings from the OPTIC (NCT02467270) and ASCEMBL (NCT03106779) studies support the use of ponatinib for patients who are highly drug-resistant and ascminib for patients with high cardiovascular risk profiles. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
